Compare TDW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDW | IDYA |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | TDW | IDYA |
|---|---|---|
| Price | $52.92 | $37.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $67.50 | $49.27 |
| AVG Volume (30 Days) | 623.9K | ★ 927.5K |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $1,361,073,000.00 | $214,834,000.00 |
| Revenue This Year | $0.76 | $2,662.86 |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | $17.95 | ★ N/A |
| Revenue Growth | 4.42 | ★ 5377.66 |
| 52 Week Low | $31.17 | $13.45 |
| 52 Week High | $64.07 | $37.08 |
| Indicator | TDW | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 67.33 |
| Support Level | $49.92 | $32.59 |
| Resistance Level | $55.07 | $35.28 |
| Average True Range (ATR) | 1.75 | 1.36 |
| MACD | 0.14 | 0.15 |
| Stochastic Oscillator | 61.12 | 78.25 |
Tidewater Inc provides marine and transportation services to the offshore energy industry. The company's vessels and associated services support all phases of offshore crude oil and natural gas (also referred to as oil and gas) exploration activities, field development, production, and maintenance, as well as windfarm development and maintenance. Its services include towing and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workovers, production activities, field abandonment, dismantlement, and restoration activities; and Others. The group manages its business through five segments including the Americas, Asia Pacific, Middle East, Europe/Mediterranean, and West Africa.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.